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Obesity-induced DNA hypermethylation of the
adiponectin gene mediates insulin resistance
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Adiponectin plays a key role in the regulation of the whole-body energy homeostasis by
modulating glucose and lipid metabolism. Although obesity-induced reduction of adiponectin
expression is primarily ascribed to a transcriptional regulation failure, the underlying
mechanisms are largely undefined. Here we show that DNA hypermethylation of a particular
region of the adiponectin promoter suppresses adiponectin expression through epigenetic
control and, in turn, exacerbates metabolic diseases in obesity. Obesity-induced,
pro-inflammatory cytokines promote DNMT1 expression and its enzymatic activity. Activated
DNMT1 selectively methylates and stimulates compact chromatin structure in the
adiponectin promoter, impeding adiponectin expression. Suppressing DNMT1 activity with a
DNMT inhibitor resulted in the amelioration of obesity-induced glucose intolerance and
insulin resistance in an adiponectin-dependent manner. These findings suggest a critical role
of adiponectin gene epigenetic control by DNMT1 in governing energy homeostasis, implying
that modulating DNMT1 activity represents a new strategy for the treatment of obesity-
related diseases.
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E
pigenetic regulation including DNA methylation is one
of the crucial mechanisms in the regulation of eukaryotic
gene expression without DNA sequence modification1.
Accumulating evidence has indicated that DNA methylation
would serve as a bridge between environmental changes
and cellular responses. Of note, nutrient status differentially
modulates DNA methylation in several metabolic genes including
hepatocyte nuclear factor 4a, pancreatic and duodenal homeobox
1 (Pdx1), peroxisome proliferator-activated receptor (Ppar)
g coactivaotr-1 a (Pgc-1a)2–5. Intriguingly, several reports have
demonstrated that high-fat diet (HFD) consumption affects
the epigenetics of various genes involved in the inheritance of
metabolic imbalance to the following generation, which is
associated with insulin sensitivity6,7.
Adiponectin, which is selectively expressed in adipocytes,
modulates whole-body energy homeostasis by regulating
glucose and lipid metabolism8,9. In metabolic tissues,
adiponectin enhances insulin sensitivity via promoting glucose
utilization and fatty acid oxidation9,10. In addition, adiponectin
suppresses obesity-induced immune responses and development
of atherogenic risk factors11,12. Accordingly, supplementation
of adiponectin or adiponectin receptor agonist improves insulin
sensitivity and metabolic parameters in obese animal models13,14.
Interestingly, adiponectin expression and its serum levels are
negatively correlated with obesity and obesity-related metabolic
diseases such as insulin resistance, type 2 diabetes and
cardiovascular diseases15.
Generally, adiponectin expression is governed in several
regulatory steps such as transcriptional and post-translational
regulation including oligomer assembly and secretion. In obesity,
such regulatory mechanism of adiponectin is disrupted by multiple
factors including adipocyte hypertrophy, inflammation and
oxidative stress, leading to hypoadiponectinemia15–17. Among
them, mounting evidence suggests that hypoadiponectinaemia in
obesity is primarily ascribed to a failure of transcriptional
regulation15,18,19. Importantly, the underlying molecular
mechanism mediating such dysregulation in obesity has not been
elucidated. In particular, it has not been explored whether
epigenetic changes such as DNA methylation play roles in the
dysregulation of adiponectin gene expression in obesity.
In this study, we have investigated the role of DNA
methylation in adiponectin gene expression. We revealed that
the hypermethylation of adiponectin promoter inhibits
adiponectin transcription. Moreover, DNA methylation at the
adiponectin promoter is mediated by DNA methyltransferase
(DNMT) 1 whose expression is elevated in adipocytes of
obese subjects. In addition, stimulation of adiponectin expression
by the suppression of DNMT1 activity repressed inflammatory
responses and increased insulin sensitivity in obese mice,
which would provide novel insights into mechanisms under-
pinning the reprogramming of adiponectin gene expression by
DNA methylation in metabolic complications.
Results
Adiponectin promoter is hypermethylated in obese subjects.
Consistent with previous reports15,18,19, adiponectin mRNA
levels were significantly reduced in adipocytes from HFD-fed
obese mice, whereas mRNA levels of key adiponectin-regulatory
transcription factors, including Pparg2 or CCAAT/enhancer-
binding protein a (C/ebpa) were not significantly altered
(Supplementary Fig. 1a). This observation led us to speculate
the possibility of alternative pathways involved in the
transcriptional repression of adiponectin in obesity. Among
various biological processes, DNA methylation is one of the key
transcriptional regulatory mechanisms governing the accessibility
of the transcription machinery to target sites through modulation
of the chromatin structure20. Furthermore, recent findings have
shown that DNA methylation is an active regulatory mechanism
responding to the changes in nutrient cues with multiple impacts
on the regulation of systemic energy homeostasis2–7.
To gain insight into the involvement of DNA methylation in
the obesity-induced decrease of adiponectin expression, we used
bisulfite sequencing analysis to investigate the DNA methylation
levels of the adiponectin promoter in adipocytes isolated from
normal chow diet (NCD)- or HFD-fed mice. There are six CpG
dinucleotides within the 1.2-kb upstream region of the mouse
adiponectin gene promoter (Supplementary Fig. 1b). The degree
of DNA methylation of the adiponectin promoter was examined
in two regions—R1 (relatively close to the transcription start site
and R2 (positioned 1 kb upstream of the transcription start site;
Supplementary Fig. 1b). Interestingly, the R2 was highly
methylated in adipocytes from HFD-fed obese mice as compared
with NCD-fed lean mice (Fig. 1a,b). Moreover, R2 methylation
levels were inversely correlated with the amounts of adiponectin
mRNA (Fig. 1c). Likewise, the R2 was hypermethylated and
adiponectin gene expression significantly decreased in adipocytes
of genetically obese db/db mice (Fig. 1d–f, Supplementary
Fig. 1c). By contrast, the R1 methylation was unaltered regardless
of obesity (Supplementary Fig. 1d–i). Notably, obesity-associated
hypermethylation was specific to the adiponectin promoter,
whereas methylation levels in the promoters of other genes,
including Pparg2 or Tnfa, were not promptly affected
(Supplementary Fig. 1j–u), suggesting that DNA methylation
would participate in the obesity-induced alteration of gene
expression in a gene-specific manner. Further, we examined
whether human adiponectin expression was associated with
DNA methylation of the human adiponectin promoter contain-
ing three CpG dinucleotides in a region that shows high
homology with the R2 of the mouse adiponectin promoter
(Supplementary Fig. 2). In human adipocytes, the R2 methylation
was not only positively correlated with body mass index
(Fig. 1g,h) but also negatively associated with adiponectin
transcripts (Fig. 1i), findings that further support the potential
role of DNA methylation in the R2 to mediate obesity-induced
dysregulation of adiponectin expression.
DNMT1 governs adiponectin gene expression via R2 methylation.
Next, we verified which DNMTs among the three isoforms in
mammals, DNMT1, DNMT3a and DNMT3b, were responsible for
the obesity-induced R2 hypermethylation. Examination of
DNMT expression in adipocytes indicated that the level of Dnmt1
mRNA was exclusively decremented in mature adipocytes that
predominantly contribute to adiponectin expression (Supplementary
Fig. 3a,b). Moreover, Dnmt1 expression was elevated in adipocytes
from HFD-fed and db/db mice compared with that from NCD-fed
or wild-type (WT) lean mice (Fig. 2a). Importantly, DNMT1
expression in human adipocytes showed a positive correlation with
body mass index (Fig. 2b). Indeed, DNMT1 knockdown in
differentiating adipocytes led to a selective increase of both
adiponectin mRNA and protein expression with a significant
reduction of the R2 methylation (Fig. 2c–e), whereas DNMT3a
suppression did not significantly influence adiponectin gene
expression (Supplementary Fig. 3c). Conversely, DNMT1
overexpression significantly decreased the adiponectin mRNA level,
concomitant with hypermethylation of the R2 (Fig. 2f–h), but
not the R1 (Supplementary Fig. 3d). Furthermore, mutation of all
CpGs to CpCs at the R2 mitigated DNMT1-induced decrease in
adiponectin promoter activity in adipocytes (Supplementary Fig. 3e),
arguing that DNMT1 indeed inhibits adiponectin expression in a
DNA methylation-dependent manner. Compelling evidence
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indicates that the suppression of gene expression by DNA methy-
lation is linked with chromatin remodelling20,21. Notably, the two
AluI restriction sites in the R2 (Fig. 2i) became resistant to AluI
enzyme digestion on HFD feeding (Fig. 2j), suggesting the formation
of a compact chromatin structure around the hypermethylated R2.
Inflammatory cytokines promote DNA methylation at the R2.
To understand the molecular mechanisms of obesity-induced
adiponectin promoter hypermethylation, differentiated adipocytes
were challenged with several stimuli suppressing adiponectin
expression, including pro-inflammatory cytokines, endoplasmic
reticulum stress, mitochondrial dysfunction or hypoxic environ-
ment22–24. Although the above factors potently suppressed
adiponectin gene expression, only pro-inflammatory cytokines
such as tumour necrosis factor (TNFa) and interleukin (IL)-1b
were able to induce Dnmt1 expression and activity (Fig. 3a,b and
Supplementary Fig. 4a), potentiating hypermethylation of the R2
but not the R1 (Fig. 3c–e, Supplementary Fig. 4b, and
Supplementary Fig. 5). Further, NF-kB signalling pathway
appeared to be engaged in cytokine-induced stimulation of
DNMT1 as treatment of Bay-11–7082 (BAY), an inhibitor of
NF-kB, substantially reduced the level of DNMT1 expression
induced by TNFa (Supplementary Fig. 6). In addition, TNFa
induced a closed chromatin structure in the R2 (Fig. 3f) and
enhanced the recruitment of DNMT1 and methyl CpG-binding
protein 2 (MeCP2), a methyl-DNA-binding protein that
interacts with histone-modifying enzymes to the R2 (Fig. 3g).
Simultaneously, the level of H3K9 acetylation (H3K9Ac) at the R2
decreased in TNFa-treated adipocytes (Fig. 3g).
DNMT inhibition alleviates the effect of TNFa on adiponectin.
To examine whether the R2 hypermethylation is involved in
the inflammation-mediated downregulation of adiponectin
expression, we used RG108, a DNMT inhibitor. In adipocytes,
RG108 decreased TNFa-induced DNMT1 activity, while Dnmt1
mRNA level was elevated by TNFa (Fig. 4a,b). Accordingly,
RG108 attenuated the suppression of adiponectin expression by
TNFa in conjunction with decrement of methylation level of the
R2, but not the R1 (Fig. 4c,d). Likewise, the knockdown of
DNMT1 rescued TNFa-induced the suppression of adiponectin
expression with a decrease in the R2 methylation (Fig. 4e,f).
RG108 also reversed TNFa-mediated decrement of H3K9Ac as
well as MeCP2 recruitment and consequently augmented AluI
accessibility to the R2 (Fig. 4g,h). These results strongly support
the significance of DNMT1 in regulating adiponectin expression
through enhancing promoter methylation and consequent
alteration of chromatin structure in response to pro-inflamma-
tory cytokines.
DNMT inhibitor elevates adiponectin levels in db/db mice.
Next, we administrated RG108 to db/db mice to explore the
potential roles of DNMT1 in the dysregulation of adiponectin
expression in vivo. In previous report, adiponectin-overexpressing
ob/ob mice exhibit improved insulin sensitivity with
elevated adiposity due to hyperplastic expansion of fat tissue25.
Hence, we empirically determined the proper RG108 dosage
(5.69mg kg 1  per day) that did not affect the weight of the body
or several organs (Supplementary Fig. 7a,b) and have no toxic
effect on the liver function (Supplementary Fig. 7c). Conversely,
RG108 significantly increased adiponectin mRNA and protein in
adipose tissue, synergistically leading to the enhancement of
serum adiponectin level (Fig. 5a–c). RG108 also elevated the level
of high molecular weight form of adiponectin (Fig. 5d).
Furthermore, the R2 methylation was significantly reduced in
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Figure 1 | Adiponectin promoter region 2 (R2) is hypermethylated in the adipocytes of obese subjects. (a–c) R2 bisulfite sequencing analysis in
adipocytes from NCD-fed (n¼4) or HFD-fed (n¼ 3) mice. (a) Each row indicates sequencing results of independent clones. Open circles denote
unmethylated CpGs and closed circles represent methylated CpGs. The CpG position relative to upstream transcription start site of mouse adiponectin
gene is shown below each column. (b) Percentage of R2 5-methylcytosine (5-mC). (c) Correlation of R2 DNA methylation and adiponectin mRNA levels.
mRNA levels were measured by qPCR. r2 and P values are indicated on the graph. (d–f) R2 bisulfite sequencing results in adipocytes from WT (n¼4) or
db/db (n¼4) mice. (d) Methylation status of each CpG. (e) Percentage of R2 cytosine methylation. (f) Correlation of R2 DNA methylation and adiponectin
mRNA levels. mRNA levels were measured by qPCR. r2 and P values are indicated on the graph. (g–i) Human adiponectin promoter R2 bisulfite sequencing
results in adipocytes isolated from human adipose tissue. (g) The CpG position relative to upstream transcription start site is shown blow each column.
(h) Adiponectin methylation levels in human adipocytes were negatively associated with body mass index. (i) Correlation between adiponectin mRNA
levels and R2 methylation levels in human adipocytes. mRNA levels were measured by qPCR. r2 and P values are indicated on the graph. Results are
expressed as the mean±s.e.m. *Po0.05; ***Po0.001 in a two-tailed Student’s t-test. #, individual mice.
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the adipocytes of RG108-treated db/db mice compared with that
of vehicle-treated db/db mice (Fig. 5e–g). However, the R1
methylation in adipocytes and the R2 methylation in the liver
were not altered by RG108 (Supplementary Fig. 7d–h).
RG108 improves insulin resistance via adiponectin expression.
As adiponectin actively regulates systemic energy home-
ostasis9,15,25, increased levels of adiponectin by RG108 led us to
investigate the effects of RG108 on obesity-related metabolic
complications. Remarkably, RG108 decreased the levels of fasting
glucose, fasting insulin, serum triglycerides (TG) and free
fatty acids (FFAs) in db/db mice (Fig. 6a,b). RG108 also
ameliorated systemic glucose intolerance (Fig. 6c) and
insulin signalling cascades in liver and muscle that are major
target organs of adiponectin (Fig. 6d,e). Moreover, RG108
mitigated obesity-induced chronic inflammation in adipose
tissues (Fig. 6f–h), whereas the DNA methylation degrees at
several promoters of inflammation-related genes such as Pparg2,
Tnfa and Mcp-1 were not altered by RG108 (Supplementary
Fig. 7i–n). Previous studies indicate that adiponectin
has anti-inflammatory functions in macrophages26,27,
suggesting that the suppressive effect of RG108 on adipose
tissue inflammation would be mediated through adiponectin
rather than directly altering the extent of DNA methylation of
inflammation-related genes. Furthermore, RG108 alleviated lipid
accumulation and expression of lipogenic and pro-inflammatory
genes in the liver (Fig. 6i–l). However, RG108 treatment did not
lead to significant changes in metabolic parameters in WT lean
mice (Supplementary Fig. 8), which might be attributed to the
fact that the adiponectin promoter is relatively hypomethylated in
lean mouse adipocytes. We also administered RG108 to
adiponectin and leptin receptor double knockout (DKO) mice
characterized with severely impaired systemic energy
homeostasis28. Similar to db/db mice, RG108 did not affect the
body weight and liver functions in DKO mice (Supplementary
Fig. 9a–c). In contrast, RG108 failed to induce an increment of
serum adiponectin level in DKO mice (Fig. 7a) and the beneficial
effects of RG108 on metabolic parameters were abolished in DKO
mice (Fig. 7b–g and Supplementary Fig. 9d). These results further
demonstrate that RG108 improves obesity-associated metabolic
disturbances through the upregulation of adiponectin.
The R2-binding molecules are altered by inflammation.
Because the R2 is newly discovered as one of the regulatory
elements of adiponectin, we set out to investigate the potential
regulators mediating inflammation-induced suppression of
adiponectin expression by isolating the R2-binding proteins from
adipocytes incubated with or without TNFa (Supplementary
Fig. 10a). Particularly, the binding of certain types of
transcription-regulating factors and histone-modifying enzymes
were dynamically changed on TNFa challenge (Supplementary
Fig. 10b and Supplementary Table 1). These data suggest
that obesity-induced repression of adiponectin expression
would be attributed to the DNA methylation-mediated suppres-
sion of activity of particular element in the adiponectin
promoter through controlling the binding of transcriptional
regulatory proteins including members of chromatin remodelling
complexes.
Discussion
Despite of the prominent roles of adiponectin in the control of
energy balance, the molecular mechanisms involved in
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obesity-induced dysregulation of adiponectin gene expression
have been elusive. The results presented here provide compelling
evidence that DNA methylation plays a crucial role in the
regulation of adiponectin gene expression, modulating whole-
body energy balance in obesity. In adipocytes, DNA methylation
at the particular region of adiponectin promoter, the R2, is
mediated by DNMT1, and induces the subsequent formation of
heterochromatin structure to suppress adiponectin gene expres-
sion in obesity. Further, the inhibition of DNMT activity
counteracts the downregulation of adiponectin followed by
improved metabolic parameters (Fig. 8).
Recent findings have revised the concept of DNA methylation
being a stable status except during embryogenesis and carcino-
genesis. Instead, DNA methylation appears to be dynamically
regulated responding to the changes in nutrient cues, affecting
systemic energy homeostasis29. Given the previous observations
that DNA methylation is one of the key players governing gene
expression independently of modulating expression of
transcription factors21,30, we explored the changes of DNA
methylation at the adiponectin promoter in obesity where the
expression of major transcription factors is retained. Adipocytes
isolated from both obese human and mice showed an increase in
DNA methylation at the specific CpG motifs, the R2, of adipo-
nectin promoter, concomitantly with the enhanced expression of
DNMT1. In obesity, the importance of DNA methylation to
suppress adiponectin gene expression has been assessed by using
animal models and pharmacological approaches. In db/db mice,
hypoadiponectinemia was ameliorated by the inhibition of
DNMT1 activity by RG108 through reducing DNA
hypermethylation at the R2, consequently alleviating metabolic
dysregulation. Notably, such beneficial effects were not observed
in adiponectin and leptin receptor DKO mice, indicating that
adiponectin gene expression is essential for metabolically
beneficial effects of RG108 in obese mice. Collectively, these
findings provide a novel clue to understand the cause of obesity-
induced dysregulation of adiponectin.
Because adipose tissue simultaneously faces interrelated
metabolic complications including chronic inflammation,
endoplasmic reticulum stress, mitochondrial dysfunction and
hypoxia in obesity31,32, we investigated which factors play critical
roles in DNMT1-mediated suppression of adiponectin gene
expression in adipocytes, Here we found that pro-inflammatory
signalling such as TNFa and IL-1b stimulated DNMT1
expression/activity and enhanced DNA methylation at the R2
in adipocytes, suppressing adiponectin expression. On the other
hand, acute treatment of tunicamycin, rotenone or hypoxia
potently repressed adiponectin gene expression regardless of
DNMT1 expression and subsequent DNA methylation.
Nonetheless, these pathophysiological conditions share many
players and points of crosstalk ultimately leading to the
dysregulation of adipose tissues31. Thus, obesity-induced
hypermethylation of the R2 in vivo is more likely due to the
accumulation of pro-inflammatory responses by multi factors
involved in the dysregulation of adipose tissues.
In the present study, we found several candidates associated
either with the R2 or R2-bound proteins in response to pro-
inflammatory stimulation. There were increases in the binding of
certain types of transcriptional regulatory proteins engaged in
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Figure 3 | Inflammatory cytokines inhibit adiponectin expression by inducing DNMT1 expression and R2 DNA methylation. Differentiated 3T3-L1
adipocytes were incubated with or without TNFa (10 ngml 1) or IL-1b (10 ngml 1) for 24 h. (a,b) Adiponectin, Dnmt1 and Mcp-1 mRNA levels. (c) DNMT
relative enzymatic activity. (d,e) R2 bisulfite sequencing analysis and quantification of 5-mC. (f) Restriction enzyme accessibility assay. mRNA levels were
measured by qPCR. (g) R2 ChIP analysis. Results are expressed as the mean value±s.e.m. of three independent samples (n¼ 3). Similar results were
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histone modification to the R2. For example, splicing factor
proline- and glutamine-rich (SFPQ) and delta 3-like E3 ubiquitin
ligase (DTX3L), which were recruited to the R2 on TNFa, are
known to be involved in transcriptional repression and chromatin
remodelling33,34. In addition, as suggested by other reports35–37,
DNMT1 has the ability to methylate selective DNA sequences
through forming complexes with specific transcription
factors. Thus, it is likely that DNMT1 is guided to the R2 by
interacting with particular transcription factor(s) whose
binding to the R2 would be altered in obesity. Accordingly, it is
clearly of importance to clarify the roles of these newly identified
proteins in the obesity-mediated suppression of adiponectin in
future studies.
Previous studies have addressed the correlation between
human adiponectin single-nucleotide polymorphisms (SNPs)
and serum adiponectin levels38–42. Interestingly, two SNPs
(rs17300539 and rs266729), which show significant correlation
with serum adiponectin levels43–46, are located within the R2 of
the human adiponectin promoter and can serve as CpG
dinucleotides as the C is located in the front position of each
SNP (Supplementary Fig. 2). For instance, human subjects with a
G to A substitution (rs17300539 A/A genotype) exhibit higher
plasma adiponectin levels than subjects with the rs17300539 G/G
genotype. Likewise, human subjects with a C to G substitution
(rs266729 G/G genotype) present a lower adiponectin plasma
concentration as compared with subjects with the C/C genotype.
Therefore, our findings and the human SNP data strongly
support the critical role of DNA hypermethylation in the
suppression of adiponectin expression.
Taken together, this study illustrates one of the key regulatory
regions in the adiponectin gene whose DNA modification and
chromatin remodelling are important for obesity-induced
suppression of adiponectin expression. Particularly, these data
demonstrate the feasibility of stimulation of adiponectin expres-
sion by DNMT inhibitor for the potential therapeutics against
obesity-related disease.
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Methods
Animal experiments. Six or 8-week-old C57BLKS/J-Leprdb/Leprdb (db/db) male,
C57BLKS/J-mþ male and 8-week-old C57BL/6J male mice were purchased from
Central Laboratory Animal Inc. Eight to 10-week-old db/db mice and leptin
receptor / /adiponectin / DKO male mice with a C57BL/6J background were
also used28. For the HFD study, 8-week-old mice were fed a NCD or 60% HFD
(Research Diet Inc., D12492) for 20 weeks. For the DNMT inhibitor injection study,
8-week-old WT or db/db mice were intraperitoneally injected with vehicle (Veh, 1%
DMSO (dimethylsulphoxide) in PBS) or RG108 (Cayman, 13302; 5.69mgkg 1 per
day) for 32 days. To measure fasting glucose and fasting insulin levels, WT or db/db
mice were fasted for 16 h and basal blood samples were drawn. For the oral glucose
tolerance test (OGTT), WT or db/db mice were fasted for 6 or 16 h, respectively,
followed by oral gavage of 2 g kg 1 or 1 g kg 1 glucose bolus. Blood glucose levels
were measured 0, 15, 30, 45, 60, 90 and 120min after oral gavage. For the DNMT
inhibitor injection study using db/db and DKO mice, 8–10-week-old mice were
intraperitoneally injected with Veh or RG108 (5.69mg kg 1  per day) for the first 2
weeks and then increased to 8.2mg kg 1  per day for the remaining 3 weeks. The
GTT was performed by intraperitoneal injection of glucose at 1 g kg 1 body weight,
followed by measurement of blood glucose 0, 15, 30, 45, 60, 75, 90 and 120min after
intraperitoneal injection. All animal experiments were approved by the Seoul
National University Animal Experiment Ethics Committee and the Committee on
the Use of Live Animals for Teaching and Research of the University of Hong Kong.
Serum protein and lipid measurements. Serum insulin levels were measured
by an enzyme-linked immunosorbent assay (ELISA) (Shibayagi Co. Ltd.,
AKRIN-001T). Serum alanine aminotransferase and aspartate aminotransferase
activities were measured using an activity assay kit (Biovision, K752-100, K753-100
and Sigma Aldrich, MAK052-1KT, MAK055-1KT). Assay kits were used to mea-
sure serum TG (Thermo Fischer Scientific Inc., TR22321 and Sigma Aldrich,
T2449-10ML) and FFA (Roche, 11 383 174 001). Adiponectin serum levels were
measured using a homemade ELISA kit (The University of Hong Kong). Analysis
and quantification of adiponectin oligomerization were performed using gel
filtration as described previously47. In brief, 10 ml of serum was diluted with 1ml
of PBS. Diluted serums were loaded onto an AKTA explorer fast protein
chromatography system, fractionated through a Hiload 16/60 Superdex 200
column (GE Healthcare, 28-9893-35) and eluted with PBS at a flow rate of
1mlmin 1. Each 0.5-ml fraction was collected and subjected to ELISA analysis.
Human samples. Human adipose tissue samples were obtained from 12 subjects
from the Obesity Research Center at the College of Medicine of King Saud
University, Riyadh, Saudi Arabia. The protocol was approved by the College of
Medicine Ethics Committee, King Saud University, and written informed consent
was obtained from all participants to their enrollment in the study. After adipocyte
fractionation and genomic DNA extraction, methylation levels of the adiponectin
promoter R2 region were analysed by bisulfite sequencing. Following RNA
extraction, RNA was reverse transcribed to complementary DNA (cDNA) and then
used in quantitative real-time PCR (qPCR).
Adipose tissue fractionation and flow cytometry. Epididymal adipose tissues
were isolated from each mouse, rinsed in PBS, minced and digested for 35min at
37 C in Krebs–Ringer phosphate buffer (pH 7.4) with 2% bovine serum albumin
and 1.75mgml 1 of type I collagenase (Gibco, 17100-017). The digested tissue was
filtered through a 250-mm nylon mesh to remove undigested tissue and centrifuged
at 3,000 r.p.m. for 5min. The floating adipocyte fraction and SVC pellet were washed
several times. Flow cytometry analysis of adipose tissue macrophage was performed
as described previously48. In brief, SVC pellets were incubated with red blood cell
lysis buffer (eBioscience, 00-4333-57) for 5min. After washing twice with PBS, SVC
pellets were incubated with CD16/32 (eBioscience, 14-0161), as blocking antibody,
for 10min at 4 C to staining with fluorescence-labelled primary antibodies for
30min at 4 C. Cells were gently washed with and resuspended in PBS. SVCs were
analysed using the fluorescence-activated cell sorting CantoII instrument (BD
Bioscience). The following antibodies were used for flow cytometry analysis—anti-
CD11b (eBioscience, 27-0112-81, 1:50 dilution), anti-F4/80 (eBioscience,
45-4801-80, 1:50 dilution) and anti-CD11c (eBioscience, 12-0114-82, 1:50 dilution).
Genomic DNA purification and bisulfite sequencing. DNA was purified by
phenol–chloroform extraction. Cells were lysed for 1 h in lysis buffer (50mM Tris-
Cl (pH 8.0), 50mM ethylenediaminetetraacetic acid (EDTA; pH 8.0), 100mM
NaCl, 2% SDS and 20mgml 1 RNase) at 37 C and digested with 10mgml 1
proteinase K for 3 h at 50 C. Bisulfite conversion was performed using the EpiTect
Bisulfite Kit (Qiagen, 59104). Converted DNA was amplified by PCR using primers
designed with Methprimer software (www.urogene.org/methprimer/index1.html).
PCR conditions were 95 C for 7min and 35 cycles of 95 C 1min, 55 C 30 s and
72 C 1min, followed by 10min at 72 C. PCR products cloned into bacteria using
the TOPO TA cloning kit (Invitrogen, 450641). Eight clones for each sample were
sequenced using COSMO Genetech commercial services. The primer sequences
that were used for PCR are provided in Supplementary Table 2.
Cell culture and transient transfection. 3T3-L1 cells were obtained from ATCC
(CL-173). 3T3-L1 cells were grown to confluence in Dulbecco’s modified Eagle
medium (DMEM; Hyclone, SH30243.01) supplemented with 10% bovine calf
serum (Gibco, 26010-074). To induce adipocyte differentiation, at 2 days post
confluence, 3T3-L1 cells were incubated with DMEM containing 10% fetal bovine
serum (FBS; Hyclone, SH30919.03), 0.52mM 3-isobutyl-1-methylxanthine
(Sigma Aldrich, I5879), 1 mM dexamethasone (Sigma Aldrich, D1756) and
1 mgml 1 insulin (Roche, 11 376 497 001) for 2 days. Then, the culture medium
was replaced with DMEM containing 10% FBS and 1 mgml 1 insulin and the cells
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were cultured for 2 additional days. The culture medium was changed every 2 days
with DMEM containing 10% FBS.
Small interfering RNA duplexes were designed and purchased from Bioneer
(DNMT1, 1350629; DNMT3a, 1350650). pcDNA3-DNMT1 vector was kindly
donated by Dr Francois Fuks (Free University of Brussels, Belgium). Each small
interfering RNA (20mM), pcDNA3.1-myc-His and pcDNA3.1-DNMT1 were
delivered into 3T3-L1 cells using Microporator (Digital Bio Technology Co. Ltd.).
For the various pathological environmental-mimicking experiments,
differentiated 3T3-L1 adipocytes were incubated with or without 10 ngml 1 TNFa
(R&D Systems, 210-TA), 10 ngml 1 IL-1b (R&D Systems, 201-LB), 1 mgml 1
tunicamycin (Calbiochem, 654080), 1 mM rotenone (Sigma Aldrich, R8875) or
incubated in normal or hypoxic (1% O2 concentration) conditions for 24 h. To
inhibit DNMT1 activity, 3T3-L1 adipocytes were preincubated with RG108
(100 mM) for 24 h before treatment with TNFa.
RNA isolation and qPCR. The RNA isolation and cDNA synthesis procedure were
performed as described previously49. In brief, total RNA was isolated from mouse
cells or cell lines with TRIzol Reagent (Ambion, 15596-018) and subjected to
cDNA synthesis using Maxima First Strand cDNA synthesis Kit for qPCR (Thermo
Scientific, K1642). RNA from purified human adipocytes was extracted using the
RNeasy Lipid Tissue kit (Qiagen, 74804), and subjected to cDNA synthesis using
the High Capacity RNA-to-cDNA kit (Applied Biosystems, 4387406). mRNA
relative amounts were measured using the CFX96 Real-Time System (Bio-Rad
Laboratories Inc.) and calculated by normalization to the level of cyclophilin
mRNA (mouse cells or cell lines), or to the level of GAPDH mRNA (human cells).
The primer sequences that were used for quantitative real-time PCR analyses are
provided in Supplementary Table 3.
Restriction enzyme accessibility assay. The restriction enzyme accessibility
assay has been described previously50. In brief, adipocytes from epididymal adipose
tissue and 3T3-L1 cells were harvested with RSB buffer (10mM Tris-HCl (pH 7.4),
10mM NaCl, 5mM MgCl2, 0.1% Nonidet P-40 (NP-40), 5mM butyrate, 10mM
NaF and 1mM NaVO7, supplemented with protease inhibitors) and incubated for
20min on ice. The cell pellets were homogenized through 27-gauge syringes,
centrifuged at 2,000 r.p.m. at 4 C for 5min and resuspended in 100ml of fresh RSB
buffer. Resuspended gDNA was digested with 100U of AluI, EcoRI and BamHI
(TaKaRa, 1004A, 1040A and 1010A). Reactions were stopped by adding proteinase
K and 2% SDS for 6 h at 45 C. Chromosomal DNA was then extracted with
phenol–chloroform twice, precipitated with isopropanol and resuspended in
distilled water. The precipitated DNA was amplified by PCR. Relative amounts
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of PCR product were measured using the CFX96 Real-Time System (Bio-Rad
Laboratories Inc.) The primer sequences that were used for PCR are provided in
Supplementary Table 2.
Chromatin immunoprecipitation. 3T3-L1 cells were crosslinked in 1% for-
maldehyde at room temperature for 10min, and crosslinking was terminated by
the addition of glycine (125mM) for 2min. After a rinse with PBS, cells were
collected with buffer 1 (100mM Tris-HCl (pH 9.4) and 10mM dithiothreitol
(DTT)). For the isolation of crude nuclei, cell pellets were resuspended with buffer
2 (10mM Tris-HCl (pH 8.0), 0.25% Triton-X-100, 0.5% NP-40, 10mM EDTA,
0.5mM EGTA and 1mM DTT) for 10min and precipitated with centrifugation.
Collected nuclei were washed with buffer 3 (10mM Tris-HCl (pH 8.0), 0.2M NaCl,
1mM EDTA, 0.5mM EGTA and 1mM DTT) twice and resuspended in buffer 3
without NaCl for sonication. After sonication, equal amounts of chromatin solu-
tion were incubated in 1 radioimmunoprecipitation assay buffer with antibodies
at 4 C overnight. The immunoprecipitates were collected by adding protein
A-sepharose beads and sequentially washed with modified TSE (mTSE) 1 (0.1%
SDS, 0.5% Triton-X-100, 2mM EDTA, 20mM Tris-HCl (pH 8.0), and 100mM
NaCl), mTSE2 (0.1% SDS, 0.5% Triton-X-100, 2mM EDTA, 20mM Tris-HCl (pH
8.0) and 200mM NaCl), mTSE3 (0.25M LiCl, 0.5% NP-40, 1mM EDTA, 10mM
Tris-HCl (pH 8.0)) and TE (10mM Tris-HCl (pH 8.0) and 1mM EDTA) buffers.
Then, immune complexes were eluted with elution buffer (1% SDS and 0.1M
NaHCO3), and the protein–DNA crosslinking was reversed by incubating at 65 C
for 12 h with 200mM of NaCl. DNA was extracted with phenol/chloroform and
precipitated with ethanol and 20 mg of glycogen. Relative amounts of PCR product
were measured using the CFX96 Real-Time System (Bio-Rad Laboratories Inc.)
The primer sequences that were used for PCR are provided in Supplementary
Table 2. The following antibodies were used for chromatin immunoprecipitation—
anti-DNMT1 (ab92453, used 5 mg for 20mg chromatin), anti-MeCP2 (ab2828, used
5 mg for 20 mg chromatin) and anti-H2K9Ac (ab4441, used 1 mg for 20 mg
chromatin) from Abcam.
Western blotting. Cells and tissues were lysed in TGN buffer (150mM NaCl,
50mM Tris-HCl (pH 7.5), 0.2% NP-40, 1mM phenylmethylsulfonyl fluoride,
100mM NaF, 1mM Na3VO4, 10mgml 1 aprotinin, 2mgml 1 pepstatin A and
10mgml 1 leupeptin) and radioimmunoprecipitation assay buffer, respectively.
Proteins were separated by electrophoresis on SDS–polyacrylamide gels and trans-
ferred to polyvinylidene difluoride membranes (Millipore Corp., IPVH00010). After
transfer, the membranes were blocked with 5% non-fat milk and probed with pri-
mary antibodies. Antibodies against adiponectin (Cell Signaling, 2789, 1:1,000
dilution), b-actin (Sigma Aldrich, A5316, 1: 2,000 dilution), PPARg (Santa Cruz
Biotechnology Inc., 7,196, 1:1,000 dilution), DNMT1 (Abcam, ab13537, 1:500
dilution), AKT (Cell Signaling, 9,272, 1:1,000 dilution), pAKT (Cell Signaling, 4051,
1:1,000 dilution), GSK3b (BD Sciences, 610201, 1:1,000 dilution) and pGSK3b (Cell
Signaling, 9,336, 1:1,000 dilution) were used. The bands were visualized with
horseradish peroxidase-conjugated secondary anti-rabbit IgG or anti-mouse IgG
antibodies (Sigma Aldrich, A0545 and A9044, respectively) and enhanced chemi-
luminescence. When liver and muscle tissues were collected from insulin-treated
mice, the mice were fasted for 16 h, and then 0.75mUg 1 body weight of insulin
was intraperitoneal injected. Liver and muscle tissues were collected 30min later.
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Figure 7 | The effects of RG108 on the metabolic parameters abrogated in adiponectin and leptin receptor DKO mice. db/db or adiponectin and leptin
receptor DKO mice were injected with vehicle (1% DMSO; Veh, n¼4–5) or RG108 (n¼4–5). (a) Serum adiponectin levels were determined by ELISA.
(b) Serum fasting glucose and insulin levels. (c) Serum TG levels. (d) OGTT. After 16-h fasting, mice were intraperitoneally injected with 1 g kg 1 body
weight of glucose and the blood glucose levels were monitored. Time course of blood clearance and AUC are presented. (e) mRNA levels of inflammatory
genes were examined in eWAT. mRNA levels were measured by qPCR. (f) Histological analysis of the liver (H&E staining). Scale bar, 50mm. (g) Hepatic TG
contents. Results are expressed as the mean±s.e.m. *Po0.05; **Po0.01; ***Po0.001 in a two-tailed Student’s t-tests.
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Figure 8 | Overall model. In obesity, increased DNMT1 induces DNA
hypermethylation at the particular region (R2) of adiponectin promoter,
resulting in suppression of adiponectin gene expression in adipocytes.
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DNMT enzymatic activity assay. To purify nuclear extracts, cells were collected
in hypotonic buffer (50mM KCl, 25mM HEPES (pH 7.8), protease inhibitor
cocktail (GeneDEPOT, P3100)) with 0.5% NP-40. Collected cells were incubated
on ice for 10min and washed with hypotonic buffer without NP-40 twice. After
removing the supernatant, pellets were resuspended with nucleus extraction buffer
(500mM KCl, 10% glycerol, 25mM HEPES (pH 7.8), protease inhibitor cocktail)
and incubated for 5min. The supernatant was collected for nuclear protein
assessment after centrifugation. The DNMT enzymatic activity assay was per-
formed using the EpiQuik DNA Methyltransferase Activity/Inhibition Assay Kit
(Epigentek Group Inc., P-3001) with nuclear extract.
Purification and characterization of the R2-binding protein. To obtain the
nuclear extracts, vehicle- or TNFa-treated differentiated 3T3-L1 cells were washed
twice with cold PBS and treated with hypertonic buffer A (50mM KCl, 0.5%
NP-40, 25mM HEPES (pH 7.8) and protease inhibitor cocktail) for 5min on ice.
After centrifugation, the nuclei were washed twice with hypotonic buffer A without
NP-40. The pellets were resuspended with high salt buffer B (500mM KCl, 25mM
HEPES (pH 7.8), 10% glycerol and protease inhibitor cocktail) and pipetted several
times. After centrifugation, the supernatant was collected and used for pull-down
assay. We designed the oligonucleotides containing the R2. After synthesis, the
oligonucleotides were biotinylated and annealed according to the manufacturer’s
protocol (Thermo Scientific, 89818). The oligonucleotide duplex was incubated
with nuclear extracts for overnight at 4 C. Complex of the oligonucleotides and
protein was precipitated by streptavidin-coated bead (Thermo Scientific, 20359).
The oligonucleotide-binding proteins were obtained using on-bead digestion
methods51. These were then subjected to mass spectrometry. The following
oligonucleotide sequences were used for pull-down assay; forward (f), 50-GATT
CACGATTTAATTCAAAAGCTTTGTGCTCCCGAGAATCAGCTCTGGTCTTT
CAAAAATAAGATGTGAGTCCGCCGAGAGGCTCCCAAGGTATTGCCTTG
CCAAC-30 ; reverse (r), 50-GTTGGCAAGGCAATACCTTGGGAGCCTCTCG
GCGGACTCACATCTTATTTTTGAAAGACCAGAGCTGATTCTCGGGAGC
ACAAAGCTTTTGAATTAAATCGTGAATC-30 .
Statistical analysis. All the results are presented as mean±s.e.m. Statistical sig-
nificance was assessed by the two-tailed Student’s t-test using GraphPad Prism 5.0
(GraphPad Software). There was no difference in variances for all comparisons in
F-test. When cells were used for experiments, three replicates per group were
chosen. All n values defined in the legends refer to biological replicates unless
otherwise indicated. In mouse experiments requiring technical manipulation, at
least five mice were used per group. If technical failures such as failure of oral
gavage and intraperitoneal injection occurred, those samples were excluded from
the final analysis. Differences were considered statistically significant at Po0.05.
No statistical method was used to predetermine sample size. The experiments were
not randomized. The investigators were not blinded to allocation during experi-
ments and outcome assessment.
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